Biotechnology Focus

Laboratory Focus September 2011

Biotechnology Focus is Canada's leading authority on Canada's life science news. From biopharma and healthcare to ag-bio and clean tech, our readership includes life science professionals, C-level executives and researchers.

Issue link: http://biotechnologyfocus.uberflip.com/i/95194

Contents of this Issue

Navigation

Page 5 of 19

6 September 2011 Laboratory Focus www.bioscienceworld.ca APPOINTMENTS Acasti Pharma Inc., a subsid- iary of Neptune Technologies & Bioressources Inc., appoints Dr. Harlan Waksal as executive vice- president, Business & Scientific Affairs. Dr. Harlan Waksal will be involved in the execution of the company's clinical development program which will lead to an Investigational New Drug (IND) ap- plication with the Food and Drug Administration (FDA) of the U.S. Dr. Waksal will also be involved in other scientific operations as well as in business development. Dr. Harlan Waksal is a physician, co-founder of ImClone System In- corporated and from 1987 to 2003 he held various positions at the company which included serving on the ImClone board of directors, chief operating officer and execu- tive vice-president, the president and CEO. Dr. Waksal currently serves on the Board of directors of Oberlin College and Senesco Tech- nologies, Inc. He is the author of over 50 scientific publications and has been the inventor of multiple patents and patent applications. Maker of COLD-FX® Afexa Life Sciences Inc. announces the ap- pointment of Annalisa King, Senior held senior positions, primarily in finance, throughout her career at consumer packaged goods compa- nies Kraft and Pillsbury Canada. She is also an inductee of Canada's Most Powerful Women: Top 100 Hall of Fame. vice president and CFO of Best Buy Canada Ltd., to its board of direc- tors. Ms. King brings the board complement to eight. Prior to join- ing Best Buy Canada Ltd., Ms. King was the senior vice president of Business Transformation for Maple Leaf Foods in Toronto, ON. She has Continuing Education for Chemical Professionals LABORATORY SAFETY COURSE September 19–20, 2011 Vancouver, BC October, 24–25, 2011 London, Ont. For → Chemists and chemical technologists whose responsibilities include managing, conducting safety audits or improving the operational safety of chemical laboratories, chemical plants and research facilities. Student Members $150 *includes Laboratory Health and Safety Guidelines 4th ed. Registration Fees* CIC Members $550 Non-members $750 For more information, visit www.cheminst.ca/profdev Reply card #4475 Isotechnika Pharma Inc. an- nounces the appointment of Daniel Park to the role of chief business officer. Mr. Park will oversee all business development operations at Isotechnika, and will specifically help to lead licensing and partner- ship discussions and negotiations for voclosporin. As a member of the executive management team, he will also provide guidance and input on other key business is- sues. In addition to the CBO role Park will remain as a member of the company's Board of directors. Additionally he will maintain his position as executive vice-president of ILJIN Group, a large conglomer- ate based in South Korea with 2010 revenue of US$2 billion. He has held senior management roles since 1998 when he was vice president of ETEX Corp., and has since worked in numerous ILJIN Group compa- nies including ILJIN Display Co., Ltd. and ILJIN Diamond Co., Ltd. in senior management positions. He holds a Masters of Business Admin- istration degree from the University of California at Los Angeles, and a Masters degree in Economics from Seoul National University. Miraculins Inc. announces that April Manness has been appointed to the role of chief financial officer Miraculins receives a number of services, including the services of its CFO, through a management services agreement with Genesys Venture Inc. Manness has been an employee of GVI since 2000 and was previously the CFO of Miracu- lins from 2004 - 2007. Dr. Mark Edwards has joined AlgaeBio as an advisor to its board of directors, effective immediately. Edwards is also now vice-president of Corporate Development and Marketing with Algae Biosciences Incorporated (ABI), a wholly owned American subsidiary of AlgaeBio. Edwards, a professor of strategic marketing and sustainability at ASU's W.P. Carey School of Busi- ness, graduated from the U.S. Naval Academy in mechanical engineer- ing, oceanography, and meteorol- ogy. He founded TEAMS Intl., an advanced assessment and software company, serving as lead consultant D_Insertion_LF_switch_3.6235x4.735.indd 3 6/27/2011 9:52:08 AM for more than 600 organizations around the world. He also served as a director for the Greyhound Corporation, which then ranked 27th on the Fortune 500. Owner of MBA and PhD doctorate degrees in marketing and consumer behavior, Edwards has taught strategic mar- keting, sustainability, leadership, and entrepreneurship at ASU since 1978. He has also published more than 100 articles encompassing business and science disciplines, and the most recent nine of his 18 books are part of the Green Algae Strategy Series, which focuses on sustainable and affordable food and energy (SAFE) production. His ongoing Algae 101 column, mean- while, was named the No. 1 visited site by Algae Industry Magazine earlier this year. Oncolytics Biotech Inc. appoints Dr. George M. Gill to the role of Chief Medical Officer. He has been senior vice president of Clinical Safety and Regulatory Affairs and an officer of Oncolytics since 2002. Prior to joining Oncolytics Dr. Gill was vice president of Clini- cal Research and vice president of Medical Affairs at Ligand Pharma- ceuticals; senior director and head of U.S. Clinical and Medical Affairs for ICI Pharmaceuticals (now As- traZeneca) and vice president and head of Worldwide Regulatory Af- fairs for the Bristol-Myers company (now Bristol-Myers Squibb). Dr. Gill began his career in the industry at Hoffman-La Roche, where he held several clinical and regula- tory positions, including director of the Clinical Oncology Group and associate director of the Regulatory Affairs Department. Dr. Gill holds a B.Sc. (Chemistry) from Dickinson College in Pennsylvania and an MD from the School of Medicine of the University of Pennsylvania. He is board certified in pediatrics.

Articles in this issue

Links on this page

view archives of Biotechnology Focus - Laboratory Focus September 2011